Jame Abraham, MD, FACP, is the Director of the Breast Oncology Program at Taussig Cancer Institute and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program. Dr. Abraham is also a professor of medicine at Cleveland Clinic Lerner College of Medicine.
Dr. Abraham completed his residency at the University Of Connecticut School Of Medicine, followed by a Medical Oncology fellowship from the National Cancer Institute (NCI) and Hematology Fellowship from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Dr. Abraham earned his medical degree from Calicut Medical College, Kerala, India.
At the NCI, he was the study chair of several early-phase clinical trials that included novel treatment for breast cancer such as Ixabepilone, which was approved by FDA in 2007. During his fellowship, Dr. Abraham edited the first edition of the Bethesda Handbook of Oncology (Lippincott Williams and Wilkins) and now it is one of the best-selling oncology textbooks in the world. It is considered the standard textbook by many universities and hospitals across the world.
After finishing fellowship, Dr. Abraham joined West Virginia University in 2001 as an Assistant Professor. He was appointed Chief
of Hematology/Oncology in 2005. He was later appointed as the first Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research, and Professor of Medicine of West Virginia University (WVU).
At WVU, Dr. Abraham established the first comprehensive breast cancer program in the state of West Virginia. He received a grant from Department of Defense (Idea Award and Career Development Award) to study chemotherapy-induced cognitive impairment. His outstanding work in patient care was recognized by the Excellence in Clinical Medicine award from the Dean of the School of
Medicine in 2010.
In 2013, Dr. Abraham joined Cleveland Clinic as director of Breast Oncology Program, where he leads several national and local clinical
trials to find better treatment options for early stage, metastatic, triple negative and her-2 positive breast cancer patients. He is the vice chair of the Research Review Committee for the National Surgical Adjuvant Breast and Bowel Project NSABP and a member of
the scientific advisory board. He is the national Principal Investigator of the NSABP FB -10 (Neratinib and TDM-1) clinical trial for her-2 positive metastatic breast cancer.
Dr. Abraham’s primary focus and passion is taking care of patients with breast cancer. He has been selected by Cleveland Magazine and Newsweek as the top oncologist locally and nationally, respectively.